GPTHEALTH
GPTHEALTH
Each stock's 10,000-path forecast, rendered as light.
GPTHEALTH (GPTHEALTH) Stock Analysis & Case Study
Is GPTHEALTH a good buy? The data-driven verdict.
GPTHEALTH (GPTHEALTH) trades at ₹150,on the numbers it mixed signals, a Downstox Snapshot Score of 52/100.
On the numbers, GPTHEALTH (GPTHEALTH) mixed signals, a Downstox Snapshot Score of 52/100, weighing premium at 29.6× earnings, ROE of 28.5%, a 42% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
GPTHEALTH fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is GPTHEALTH overvalued? GPTHEALTH P/E vs its sector
GPTHEALTH's P/E of 29.6× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 1.67% dividend yield is above the peer median of 1.67%.
GPTHEALTH share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of GPTHEALTH history (-2%/yr drift, 33%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| GPTHEALTH 2027 | ₹91 | ₹138 | ₹209 | -7% |
| GPTHEALTH 2028 | ₹71 | ₹130 | ₹236 | -12% |
| GPTHEALTH 2029 | ₹58 | ₹119 | ₹248 | -19% |
| GPTHEALTH 2030 | ₹47 | ₹111 | ₹262 | -25% |
| GPTHEALTH 2031 | ₹40 | ₹104 | ₹264 | -30% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability GPTHEALTH goes up, or doubles?
The bull case for GPTHEALTH
- High return on equity (28.5%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- Strong ROCE (23.6%) shows the core business earns well above its cost of capital.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹248.
The bear case & risks
- At 29.6× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.
- A steep 89.8× price-to-book means most of the value is intangible/expectations, not assets on the books.
- The probability model is cautious 12 months out, only a 42% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹58.
GPTHEALTH volatility & expected range, how bumpy is the ride?
Over the last 2.0 years GPTHEALTH compounded at -2%/year with annualized volatility of 33%. That volatility implies a 1-year 80% range of ₹91–₹209, the honest backbone behind any single price target.
GPTHEALTH price forecast, the full 60-month probability fan
GPTHEALTH price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds GPTHEALTH hits common targets within the simulated horizon?
Full multi-horizon detail on the GPTHEALTH price target & forecast page.
GPTHEALTH Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. GPTHEALTH scores 4/9,mixed financial health.
GPTHEALTH MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy GPTHEALTH with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| ZerodhaCHEAPEST | 29.4% | 3.4× |
| Dhan | 40.0% | 2.5× |
Compare every broker on the GPTHEALTH MTF page.
GPTHEALTH vs peers,sector comparison
About GPTHEALTH: sector, index & market-cap context
GPTHEALTH (GPTHEALTH) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹1,235 Cr. See more Nifty 500 stocks.
How the GPTHEALTH Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of GPTHEALTH's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
GPTHEALTH analysis, FAQs
Is GPTHEALTH (GPTHEALTH) a good buy?
On the numbers, GPTHEALTH (GPTHEALTH) mixed signals, a Downstox Snapshot Score of 52/100, weighing premium at 29.6× earnings, ROE of 28.5%, a 42% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is GPTHEALTH overvalued or undervalued?
GPTHEALTH trades at 29.6× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the GPTHEALTH share price target for 2031?
GPTHEALTH's probability-weighted 2031 median target is ₹104, with an 80% range of ₹40–₹264 (10,000-path Monte-Carlo).
What is the probability GPTHEALTH doubles in 5 years?
The modelled probability of GPTHEALTH reaching ₹296 (2×) within 5 years is 8%.
What is the bull case for GPTHEALTH?
High return on equity (28.5%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. Strong ROCE (23.6%) shows the core business earns well above its cost of capital.
What are the risks in GPTHEALTH?
At 29.6× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished. A steep 89.8× price-to-book means most of the value is intangible/expectations, not assets on the books. The probability model is cautious 12 months out, only a 42% chance of finishing above today's price.